PHARMACOLOGY

Inflammatory definitions
Sir, in the excellent article relating to the clinical problem of paracetamol toxicity and the unnecessary plethora of paracetamolcontaining analgesics currently marketed the authors discuss paracetamol's effect on the inflammatory process. 1 They state correctly that paracetamol has been shown to reduce swelling, but confuse the issue by stating that it does not exhibit the antiinflammatory effects noted in NSAIDs (non-steroidal anti-inflammatory drugs). The traditional classification of NSAIDs with 'anti-inflammatory' effects versus the so-called analgesic-antipyretic drugs without 'anti-inflammatory' effects found in Anglo-Saxon literature and enthusiastically supported by the pharmaceutical industry is conceptually wrong.
The problem lies in the definition of 'anti-inflammatory' effects. Does 'antiinflammatory' mean reduction of the traditional clinical cardinal signs of an inflammation which are pain, swelling, reduced function, redness and local temperature elevation -where the two last signs are of little clinical relevance -or reduction of the biological modulators involved in a physiologic or pathologic inflammatory tissue reaction? The philosophical problem therein is how is the one possible without the other?
The answer is that it is not. Paracetamol (but also the other analgesic-antipyretic drugs to varying extent) share the pharmacodynamic properties of the traditional NSAIDs, but paracetamol's effects are shown in many in vitro experiments to be weaker. 2 These findings are referred to in textbooks with the statement that paracetamol is of little value as an 'anti-inflammatory' drug. It was therefore highly surprising that controlled clinical trials showed a paracetamol regimen compared with placebo 3 actually reduced objectively measured soft tissue swelling after third molar surgery on the third postoperative day much better (29%) than an ibuprofen regimen compared to placebo (11%). 4 In a repeated trial paracetamol showed almost exactly the same result (31%). 5 Other articles using an objective method to measure postoperative facial swelling after third molar surgery have shown paracetamol regimens to be superior to naproxen, and inferior to ketoprofen. 6, 7 Paracetamol is not a 'non-NSAID' . It reduces the clinical symptoms of an inflammation quite well with respect to oral surgery. Although paracetamol shows 'weak anti-inflammatory effects' the type of surgical interventions we practise may offer the optimal ambient inflammatory tissue conditions in which paracetamol works best. 
L. A. Skoglund, E. C. Vigen, Oslo
Endangered Jaborandi
Sir, one of the most important drugs for the treatment of glaucoma and xerostomia is pilocarpine. Pilocarpine is derived from the Jaborandi plant which is the only known source of pilocarpine in the world. 1 Pilocarpine hydrochloride is a direct acting cholinergic parasympathomimetic agent which stimulates secretion by exocrine glands such as the salivary, sweat, lacrimal, and respiratory mucous glands. Pilocarpine is used widely for the management of glaucoma, radiation induced xerostomia, drug induced xerostomia, Sjogren's syndrome, and xerostomia associated with cGVHD (Chronic graft-versus-host disease). Pilocarpine is derived from the leaves of Pilocarpus Microphyllus (Jaborandi) which belong to the genus Pilocarpus (Rutaceae). Pilocarpus species are found exclusively in South America, mainly in the forests of northern Brazilian states. 1 Jaborandi was first introduced to western medicine in 1873 when Symphronio Coutinho, a Brazilian doctor took the leaf sample to France. He routinely used Jaborandi leaves in his practice as a diphoretic and sialagogue. Its value in ophthalmology was a secondary discovery. Interest in the Jaborandi plant by French physicians was piqued due to its use among Brazilian Indians to promote profuse sweating and salivation. 2 Because of its commercial value, this species was exploited without control and by the 1990s it was considered an endangered species in Brazil. 1 During the dry season collectors go into the forest and strip the leaves from branches by hand. Excessive and frequent collection of leaves from the same plant does not allow full development of new leaves leading to high plant mortality and reduction in the size of new leaves. 2 Studies are being carried out to establish the biosynthetic route of this alkaloid and produce pilocarpine from callus cell lines in order to save this endangered species. 1 New methods of detection of pilocarpine are being employed. Alexndra Sawya and Ilka Abreu used HPLC-ESI-MS/MS (high-performance liquid chromatography-tandem mass spectrometry) method to detect pilocarpine in paste that is left over after industrial extraction of pilocarpine to permit additional studies of biosynthetic pathway. 3 Genetic breeding programmes have been proposed by Moura and Pinto. 4 Jaborandi, the only known source of pilocarine, is at the verge of extinction due to human impact. Overharvesting has placed many medicinal species at risk of extinction. We must safeguard our remaining medicinal treasures in the wild for future generations.
Preena Sidhu, Malaysia DOI: 10.1038/sj.bdj.2014.555
ORAL HEALTH Charcoal brushes
Sir, in certain South-East Asian countries, charcoal has been added to the bristles of toothbrushes, the bristles of which are black in colour (Fig. 1) . Manufacturers of these toothbrushes claim that the blending of charcoal into nylon bristles can reduce halitosis (as charcoal absorbs any bad odour), reduce plaque and also kill bacteria that may develop in the bristles during storage, thus reducing the bacterial contamination of toothbrushes. However, according to our knowledge, these claims are not substantiated by any scientific studies/evidence. These brushes are used and are easily available in Hong Kong, Malaysia, Singapore and worldwide via the Internet. Al-Ahmad et al. conducted a study wherein toothbrush heads were coated with silver to test for its antimicrobial effects but
SEALANT COSTS
Sir, I was interested to read the practice paper by Dr Bonetti on Evidence not practised: The underutilisation of preventive fissure sealants. 1 In the recently published clinical guideline by the Scottish Intercollegiate Guidelines Network (SIGN), 2 it has been suggested that resin-based PFSs should be applied to the permanent molars of all children as early after eruption as possible. In other words, applications should usually take place between the ages of 6-7 years for first permanent molars and 11-12 years for second permanent molars.
In 2012/13, approximately 30% of primary 7 children (mean age 11.5 years) in Scotland received PFSs. 3 In Scotland, the current cost of application of PFS to unfilled permanent molar teeth within two years of their eruption is £8.15 per tooth. 4 To increase the uptake of PFSs in first permanent molars from 30% to 60% in Scottish children aged 6-7 years, SIGN estimated that the incremental cost would be over £1 million. Similarly, over £1 million would be required to double the uptake of PFSs in second permanent molars in Scottish children aged 11-12 years. 2 It was not possible to segregate visits incorporating treatment with visits representing routine examinations in the above estimated costs; therefore, the total cost of service provision in Scotland may have been underestimated. However, potential savings from restorations avoided are also excluded. 2 Implementation of the SIGN guideline is the responsibility of each NHS board in Scotland. In NHS Lanarkshire, the NHS board where I have been working, mechanisms have already been in place to review the care provided against the guideline recommendations. This includes the appointment of an executive director, a clinical lead and a managerial lead. C. A. Yeung, Bothwell
